[
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 4,
    "category": "Effective Date"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      80,
      1000,
      91
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
    "bbox": [
      113,
      104,
      1000,
      115
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
    "bbox": [
      112,
      120,
      691,
      131
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Execution Copy",
    "bbox": [
      1000,
      157,
      1000,
      171
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
    "bbox": [
      364,
      182,
      977,
      193
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      619,
      198,
      723,
      209
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
    "bbox": [
      110,
      244,
      1000,
      256
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
    "bbox": [
      111,
      259,
      1000,
      273
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
    "bbox": [
      112,
      276,
      1000,
      286
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
    "bbox": [
      111,
      290,
      539,
      302
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "RECITALS",
    "bbox": [
      629,
      337,
      714,
      348
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
    "bbox": [
      156,
      368,
      1000,
      380
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
    "bbox": [
      110,
      384,
      1000,
      396
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "phosphatase 2;",
    "bbox": [
      113,
      400,
      224,
      411
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
    "bbox": [
      157,
      430,
      912,
      442
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
    "bbox": [
      156,
      460,
      1000,
      474
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
    "bbox": [
      111,
      477,
      1000,
      489
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
    "bbox": [
      157,
      508,
      1000,
      520
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Products (as defined below), as further described herein..",
    "bbox": [
      111,
      523,
      521,
      535
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
    "bbox": [
      155,
      554,
      1000,
      567
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
    "bbox": [
      111,
      569,
      554,
      582
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Article I.",
    "bbox": [
      639,
      616,
      703,
      627
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      616,
      638,
      726,
      650
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
    "bbox": [
      158,
      671,
      1000,
      682
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "places throughout this Agreement..",
    "bbox": [
      113,
      687,
      365,
      698
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
    "bbox": [
      156,
      717,
      1000,
      729
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "reporting obligations, consistently applied..",
    "bbox": [
      110,
      732,
      424,
      746
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  }
]